This study examined the action of cerivastatin, a new statin, in subjects with primary hypercholesterolaemia. The effects of two oral doses of cerivastatin (400 pg/day or 300 ug/day) were compared with placebo in 349 patients using a multicentre, randomized, double-blind, placebo-controlled study design. Cerivastatin treatment lasted 8 weeks and produced significant reductions in low density lipoproteincholesterol (LDL-C) levels from baseline compared with placebo. The reduction in LDL-C was significantly greater with 400 pg than with 300 pg cerivastatin. When responder rates were examined, the higher (400 ug/day] cerivastatin dose was found to be more effective in producing larger (> 40%) reductions in LDL-C levels. Cerivastatin treatment was well tolerated. Only two withdrawals due to adverse events during active treatment occurred, neither of which was considered to be due to the study medication. In *The data reported in this paper were presented at a symposium held in Marco Island, USA, on 6 -7 February H197. and were published in a journal supplement based on the proceedings 1 115 M Hanefeld, '-P Deslypere, LOse et al.
LDL-Elevated serum cholesterol, and in particular low density lipoprotein-cholesterol (LDL-CL is a major risk factor in the development of cardiovascular disease. Many epidemiological studies have documented the relationship between specific lipoprotein levels and the future development of coronary heart disease.i-' Other studies have shown that dietary and pharmacological intervention to reduce hypercholesterolaemia can reduce the risk of cardiovascular diseasev" and cause regression of existing atherosclerotic lesions. (; -9 Statins have been shown to be the most effective drugs for the treatment of primary hypercholesterolaemia.w" A new statin, cerivastatin, is a fully synthetic, pure enantiomer and has been shown to be therapeutically active at microgram doses.V In contrast, other statins, such as simvastatin and pravastatin, are effective only at milligram doses. In addition, cerivastatin is metabolized via a dual pathway, utilizing the isoenzymes P450 (CYP) 2CB and CYP 3A4Y This may give cerivastatin potential advantages in terms of safety and tolerability as possible interactions with other drugs may be minirnized.!" - 15 Previous clinical studies in patients with primary hypercholesterolaemia have shown cerivastatin to have significant effects on 116 LDL-C at oral doses of 100 ug. 200~g and 300~g once daily.12,H;,17 Studies lasting over 2 years have shown treatment to be well tolerated. '? In light of earlier studies demonstrating the effectiveness of 300 ug/day cerivastatin in patients with primary hypercholesterolaemia, this study investigated whether a higher 400-~g/day cerivastatin dose could improve its LDL-C-lowering potency without adversely affecting safety and tolerability. This was the first study to use the 400-~g/day cerivastatin dose and compare the efficacy, safety and tolerability ofthis dose with 300 pg/day cerivastatin and placebo.
PATIENTS AND METHODS

PATIENT SELECTION
For inclusion in the study, patients had to have an established diagnosis of primary hypercholesterolaemia. This was defined as a mean LDL-C level of~190 mg/dl (~4.90 mmol/l) calculated from LDL-C values at Visits 3 and 4, with individual measurements within 12% of their mean value, or~160 mg/dl (~4.12 mrnol/I] if associated with one or more of the following risk factors: male sex; family history of et al.
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premature coronary heart disease (definite myocardial infarction or sudden death before 55 years of age in a parent or sibling); current cigarette smoker (> 10 cigarettes/day); hypertension; coronary disease; low high density lipoprotein (HDL)-cholesterol concentration « 35 mg/dl [< 0.9 mmol/l]) confirmed by repeated measurement; history of definite cerebrovascular or occlusive peripheral vascular disease; obesity (body mass index> 30 kg/m"}. Triglyceride levels at Visits 3 and 4 had to be~350 mg/dl (~3.99 mmol/l).
All patients had to be ambulatory and between 18 and 75 years of age. They also had to provide informed written consent to be included in the study. The use of an investigational drug meant that female patients had to be of non-childbearing potential (either post-menopausal or surgically sterilized).
Exclusion criteria were as follows: established contraindications for statin intake; unstable cardiovascular disease including severe hypertension (diastolic pressure~115 mmHg), myocardial infarction within the past 6 months, cerebrovascular events, congestive heart failure (New York Heart Association class 3 or 4), cardiac arrhythmias; diabetes mellitus (fasting plasma glucose~140 mg/dl [~7.8 mmolll]); hypothyroidism; positive test for human immunodeficiency virus antibodies; malignancy; hepatic or renal disorders; history of pancreatitis; known muscular or neuromuscular disease; gastrointestinal disease (e.g. Crohri's disease) which could result in impaired absorption of the study drug; clinically significant ophthalmic abnormalities; nightshift workers (reversal of normal sleep/wake cycle); concomitant medication affecting lipid levels or known to interact with statins including immunosuppressants, erythromycin, vitamin tablets containing > 50 mg/day niacin, regular therapeutic use of psyllium, fish oil or excess bran for lipid lowering purposes, corticosteroids (including inhalation formulation) and androgens (for exceptions see Concomitant Therapy [below)); history of hypersensitivity to 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors; creatine phosphokinase (CK) > 3 times upper limit of normal (ULN) and/or hepatic transaminases (alanine transaminase, ALT; aspartate transaminase, AST) > 1.5 times ULN; treatment with any other investigational drug within 30 days prior to screening.
CONCOMITANT THERAPY
Concomitant therapy was permitted during the study provided it satisfied the inclusion and exclusion criteria. All concomitant treatments were fully documented and were to be kept to a minimum. Marked changes in concomitant therapy were noted and the study protocol allowed for the exclusion of efficacy data in such cases. The study protocol allowed the following cardiovascular medications: angiotensinconverting enzyme inhibitors, calcium antagonists, nitrates and digitalis. Diuretics, -blockers, and oestrogen and progesterone replacement therapy for post-menopausal women were also permitted if the dose remained unchanged for at least 8 weeks prior to screening, and was not intended to change during the study. Patients using -agonist inhalers were included, provided inhalers were not regularly used more than twice daily.
STUDY DESIGN
This was a multicentre, randomized, doubleblind, placebo-controlled study with three parallel groups. It was carried out between January and November 1995, and involved 24 centres in five European countries: one in Belgium, nine in France, seven in Germany, one The study design is summarized in Fig. 1 . During screening (Visit 1), patients underwent a complete physical examination; medical history (including hyperlipidaemia and coronary artery disease), demographic data and any concomitant diseases and/or medication use were recorded.
All patients selected for the study received counselling from a dietician in the American Heart Association (AHA)-Step-I d iet.!" Patients were assessed for inclusion in the optional 4-week washout/dietary stabilization phase. Those demonstrating adherence to the AHA-Step-I or an equivalent diet over the previous 4 weeks, and at least 4 weeks since the withdrawal of any lipid-lowering medication (6 months for probucol) could proceed straight to the placebo 'run-in' phase.
Extra-dietary education and reinforcement was available for patients requiring the washout/dietary stabilization period.
Evaluation visits during the 6-week single (patient)-blind placebo 'run-in' phase allowed dietary adherence to be assessed by the dietician and efficacy parameters to be measured ( Fig. 1) . A food diary was issued at Visit 4 and patients were required to record food intake for 3 days (2 working days and a Sunday) before Visit 5. Patient compliance during the 'run-in' period was judged by tablet counting and had to be between 80% and 120% for inclusion into the study.
Following the placebo 'run-in' phase, eligible patients were randomized at Visit 5 to one of three regimens: 400 ug/day cerivastatin, 300 ug/day cerivastatin or placebo. The six evaluation visits ( Fig. 1 ) scheduled during the treatment period 
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allowed blood samples to be taken for the measurement of efficacy parameters. A food diary was issued at Visit 10 for completion during the final 2 weeks of treatment and a complete physical examination, together with an ophthalmological examination, was performed at the final visit. This study was conducted in accordance with the guidelines of the Declaration of Helsinki and its Amendments. All patients participating in the study gave informed consent, and the study protocol was approved by the appropriate Ethics Committees of the participating countries.
EVALUATION CRITERIA
The primary efficacy parameter was the relative change in LDL-C levels from baseline to treatment endpoint. The baseline level was taken as the mean of the LDL-C values from Visits 3, 4 and 5, and the endpoint level was the value noted at the last scheduled visit from which data were recorded. The LDL-C levels were calculated using the Friedewald formula?" and values were used for an analysis of the responder rates. Efficacy analysis was performed on the intent-to-treat patient population. Patients were included in this population provided there was at least one value from LDL-C assessment at Visits 3, 4 or 5, and at least one from the treatment period.
Several secondary efficacy parameters were evaluated over the course of the study. Total cholesterol. HDL-C and triglyceride plasma concentrations were determined at all of the evaluation visits, except Visit 2. In addition, special lipid fractions were collected at the start and end of the treatment period (Visits 5 and 11). Secondary parameters were analysed to determine the relative percentage change from baseline to endpoint.
Blood samples for plasma lipid profiles and laboratory tests (serum chemistry, enzymes and haematological parameters) 119 were taken in the morning following a minimum 12 h of fasting. All test samples were analysed at a central laboratory (Pasteur Institute, Lille, France) to ensure consistency.
SAFETY AND TOLERABILITY ANALYSIS
All adverse events were documented and patients' laboratory parameters were monitored. Particular attention was paid to the serum levels of CK, AST and ALT, since statins are known to be associated with CK and hepatic transaminase abnormalities.
Serum CK > 10 times ULN required immediate discontinuation of the study medication. Patients were to be withdrawn from the study if the following severe abnormalities were observed and confirmed on repeat testing: serum CK > 5 times ULN (unless elevated levels could be explained by, for example, intramuscular injection or acute exercise) or > 3 times ULN if associated with muscular weakness or muscle pain; AST and/or ALT > 3 times ULN; plasma LDL-C < 60 mg/dl « 1.55 mmol/l). Repeat testing for elevated serum CK levels had to be scheduled within 1 week (as did repeat testing of AST and ALT levels).
STATISTICAL ANALYSIS
The sample size for the study was calculated on the basis of the estimated change in LDL-C levels from baseline. At least 102 patients were needed in each cerivastatin treatment group to detect a difference of 5% between the two cerivastatin doses with a power of 90% and a two-sided significance level of 5%. A placebo group of 51 patients was sufficient to detect a 15% difference between active treatment and placebo, with a power of more than 99% and a two-sided significance level of 5%.
Comparisons between treatment groups of the important prognostic factors at baseline were performed using either analysis of 
RESULTS
PATIENT POPULATION
A total of 506 patients were enrolled into the study and underwent laboratory tests at Visit 1. Of these, 155 were excluded from the treatment phase of the study prior to randomization, the majority (n = 126; 81%) because their laboratory results did not meet the randomization criteria. The others were omitted for non-compliance (n = 8), adverse events (n =2), withdrawal of consent (n =11), detection of exclusion criteria during the 'run-in' period (n = 5) or non-availability for evaluation visits (n = 3).
In all, 351 patients were randomized to treatment. Two patients were excluded from analysis because they were lost to follow-up with no post-randomization data, therefore 349 patients were included in the intent-totreat and safety analyses. Seventy-one patients were randomized to the placebo group, 140 patients received 300 ug/day cerivastatin, and 138 were given 400 ug/day cerivastatin. All treatments were orally administered. The median duration of therapy up to the last visit was 56 days (range 7 -79 days).
DEMOGRAPHICIBASELINE DATA
Demographic data for the intent-to-treat patient' population are shown in Table 1 . Analysis of the demographic data was performed using a logistic regression model to examine the covariables listed, and revealed no significant differences between 120 the treatment groups.
The homogeneity of the treatment groups for all baseline lipid parameters was investigated by ANOVA including 'treatment group' as a factor. Again, no significant differences were observed between the groups for LDL-C, HDL-C, total cholesterol and triglycerides. There were also no significant differences in demographic data or baseline lipid parameters between countries or treatment centres.
LDL-C CONCENTRATION
The mean overall baseline LDL-C concentration for the three randomized groups was 219.2 mg/dl (5.65 mmolll). For each individual treatment group, the mean baselines were: 400 ug/day cerivastatin, 218.2 mg/dl (5.62 mmolll); 300 ug/day cerivastatin, 223.0 mg/dl (5.75 mmolll); placebo, 231.5 mg/dl (5.97 mmolll).
Both the cerivastatin treatment groups showed a marked mean reduction in LDL-C concentrations compared with baseline, and this was maintained until the end of the treatment period. Mean decreases in LDL-C concentration of 35.8 ± 1.0% with 400 ug/day cerivastatin, and 32.5 ± 1.0% with 300 ug/day cerivastatin, were highly significant (P < 0.001) compared with placebo (increase of 0.2 ± 1.4%).
Pairwise comparison of the two cerivastatin doses showed that 400 ug/day was significantly (P < 0.05) more effective in reducing LDL-C concentrations than the lower dose. This dose-response relationship is clearly visible when responder rates for the change in mean LDL-C concentration are compared ( Table 2) .
When reductions in LDL-C concentrations up to > 30% are examined, similar percentages of patients occur in each of the cerivastatin treatment groups ( Table 2 ). In contrast, 40.6% of patients treated with 400 ug/day cerivastatin showed a reduction in LDL-C M Hanefeld, J-p Deslypere, LOse et al. The time course for treatment action showed that the effects of the 400-11g/day dose reached a plateau after 3 weeks of treatment, while the 300-11g/day dose took 4 weeks. Table 3 shows the results of analysis of the secondary efficacy criteria for the patient population. Both cerivastatin dosages produced significant improvements for the majority of parameters compared with placebo, although the differences observed between the two cerivastatin treatments were not significant, with the exception of total cholesterol (P = 0.02). The combined effect of changes in HDL-C plus total cholesterol levels generated a marked reduction in the atherogenic index (total cholesterol/HDL-C).
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OTHER LIPID PARAMETERS
SAFETY AND TOLERABILITY
ADVERSE EVENTS. During the treatment phase only one patient withdrew due to a serious adverse event: deterioration of established concomitant arteritis of the left lower limb (400-11g/day dose). This withdrawal was not considered to be related to the study medication. In addition, one patient on 300 ug/day cerivastatin died 2 days after the end of treatment. This person had underlying atherosclerotic disease and the possible relationship to the study drug was assessed as 'remote'.
The incidence of adverse events during the treatment phase of the study was low, with only a few events occurring in more than 2.5% of the patients in anyone treatment group (Table 4 ). Of these adverse events, the majority (9/15) had a higher incidence in the placebo group than with active treatment. 'Back pain' and 'headache' were the only adverse events having a higher incidence with both cerivastatin regimes than with placebo. and where the incidence increased with the higher cerivastatin dose.
The incidence of other adverse events showed no consistent pattern between the groups. 'Arthralgia'. for example, was seen most frequently with 300 ug/day cerivastatin, but its percentage was lower with 400 ug/day cerivastatin than with placebo. The frequency of 'creatine phosphokinase increase' was similar in the placebo and 400-11g/day cerivastatin group, and lowest in patients receiving 300 ug/day cerivastatin.
TABLE 2
Responder rates for change in low density lipoprotein-cholesterol from baseline to endpoint for the intent-to-treat population
LABORATORY PARAMETERS. Examination of CK, AST and ALT concentrations revealed no clinically significant changes with cerivastatin treatment compared with placebo (Table 5 ).
DISCUSSION
The results of this study showed that the 123 higher 400-11g/day cerivastatin dose produced a significant (P < 0.05) additional reduction in LDL-C levels over the marked decrease seen with 300 p.g/day cerivastatin in patients with primary hypercholesterolaemia. The additional benefits of the 400 ug/day treatment were not accompanied by any deterioration in safety or tolerability. Both cerivastatin doses were well tolerated, with only two treatment withdrawals due to adverse events, neither of which was considered to be related to the study medication.
The reductions in LDL-C seen with both cerivastatin doses were highly significant compared with placebo (P < 0.001). Cerivastatin treatment for 8 weeks produced Examination of patient responder rates also indicated that the higher cerivastatin dose was more effective at producing large reductions in LDL-C concentrations (> 40%). Overall, 40.6% of patients treated with 400 ug/day cerivastatin showed a reduction in LDL-C concentrations of> 40%, compared with 27.9% of patients receiving 300 ug/day cerivastatin.
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Cerivastatin produced reductions in LDL-C levels comparable with those seen for simvastatin in the Scandinavian Simvastatin Survival Study (4S).5 In that trial, 20 mg/day simvastatin produced a 38% reduction in LDL-C concentrations after 6 weeks of treatment. This compares with an observed reduction of about 36% after 8 weeks 400-11g/day cerivastatin treatment in the present study. In the 4S trial, simvastatin treatment was associated with a 42% reduction in the risk of coronary death compared with placebo, suggesting that similar improvements could be expected with cerivastatin treatment. The reductions in LDL-C concentration seen with cerivastatin were greater than those achieved with pravastatin in the Cholesterol and Recurrent Events'" (CARE) and the West of Scotland Coronary Prevention Study'" (WOSCOPS) studies. In the CARE study, 40 mg/day pravastatin reduced mean LDL-C concentrations by 32%, whereas in the WOSCOPS study, levels decreased by an average of 26%. Comparative investigations in placebocontrolled studies with other statins confirmed 300 ug/day cerivastatin to be 125 equally effective as 5 -40 mg/day simvastatin in a dose-titration study." In a long-term study, 300 ug/day cerivastatin produced similar reductions in LDL-C to 40 mg/day lovastatin (28.2% versus 32.4%). 20 The greater effects on LDL-C of 400 ug/day cerivastatin compared with 300 ug/day were not accompanied in the present study by any worsening of safety or tolerability profile. 'Back pain' and 'headache' did show an increased incidence with both active treatments than with placebo, and this increased with the higher dose; however, this tendency has not been observed in other clinical trials. Stein et a1. 2 5 analysed the safety and efficacy of 800 ug/day cerivastatin in 41 subjects with hypercholesterolaemia, twice the highest dose used in the present study, and showed a 44% reduction in LDL-C versus placebo with no serious side-effects. 
This present study shows that cerivastatin improves the overall lipid profile in patients ( Table 3 ). The 300-and 400-pg/day doses produced significant reductions in apolipoprotein B (24.3% and 26.2% reduction, respectively; placebo, 5.7% increase; P < 0.001) and triglycerides (17.3% and 14.8% reduction, respectively; placebo, 8.4% increase; P < 0.001). The decrease in apolipoprotein B indicates an overall fall in the number of LDL-C particles, rather than a depletion of their cholesterol levels. Reduced triglyceride concentrations are followed by decreased concentrations of small dense LDLs, which persist in the circulation and are atherogenic, accompanied by an increase in the less dense LDL 1 and LDL L subfractions.
Treatment with 300 or 400 ug/day cerivastatin also resulted in significant increases in apolipoprotein Al (5.6% or 5.0% increase, respectively; placebo, 0.5% increase; P < 0.01) and HDL-C (5.8% or 4.1%; placebo, 0.3% decrease; P < 0.02) compared with placebo. The HDL particles are vasoprotective and important in cholesterol reverse transport. Increases in their number are indicative of increased very low density lipoprotein particle turnover.
The therapeutic activity of cerivastatin at microgram doses, compared with milligram doses for other statins, may have potential advantages in terms of safety and tolerability. The low dose of cerivastatin used, together with its dual metabolic pathway!" may mean that interactions with other drugs are minimized. For example, it has been shown that cerivastatin does not alter the pharmacokinetics of digoxin14 and warfarin 15 when co-administered, unlike some other statins. It has also been shown that cerivastatin does not interfere with other compounds such as cimentidine;" orneprazole.F nifedipine" and mibefradil.P
In conclusion, cerivastatin produced significant reductions in LDL-C concentrations, with the 400-pg/day dose being significantly more effective than the 300-pg/day dose. Both dosages were well tolerated, with no indications of any specific risk of serum enzyme elevations. This study therefore confirms the value of cerivastatin treatment in patients with primary hypercholesterolaemia, and supports the view that higher doses could enhance the lipid lowering activity of cerivastatin. 
